TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2B, Multi-Center, Randomized, Double-Blinded, Parallel-Arm , Study to Assess Efficacy and Safety of 3'-Aminomethylnicotine-P. Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX®) or Placebo Co-Administered With Varenicline (Champix®) as an Aid in Smoking Cessation
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of NicVAX co-administered with varenicline as an aid in smoking cessation over a one-year period in smokers who want to quit smoking.


Options:
A: Arm Label: NicVAX conjugate vaccine; Type: EXPERIMENTAL; Interventions: Biological: NicVAX vaccine, Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Drug: Varenicline | Intervention Type: BIOLOGICAL; Name: NicVAX vaccine; Assigned to Arm(s): NicVAX conjugate vaccine | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): NicVAX conjugate vaccine, Placebo
B: Arm Label: NRT arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine Replacement Therapy (NRT) | Arm Label: NRT and HIV Tailored Quit Smoking Counseling; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine Replacement Therapy (NRT), Behavioral: HIV Tailored Quit Smoking Counseling | Arm Label: Varenicline (VR) Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Varenicline (VR) and HIV Tailored Quit Smoking Counseling; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Behavioral: HIV Tailored Quit Smoking Counseling | Intervention Type: DRUG; Name: Nicotine Replacement Therapy (NRT); Assigned to Arm(s): NRT and HIV Tailored Quit Smoking Counseling, NRT arm | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline (VR) Arm, Varenicline (VR) and HIV Tailored Quit Smoking Counseling | Intervention Type: BEHAVIORAL; Name: HIV Tailored Quit Smoking Counseling; Assigned to Arm(s): NRT and HIV Tailored Quit Smoking Counseling, Varenicline (VR) and HIV Tailored Quit Smoking Counseling
C: Arm Label: Varenicline treatment as usual (TAU); Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Varenicline directly observed therapy; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline directly observed therapy, Varenicline treatment as usual (TAU)
D: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline(Chantix) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline(Chantix); Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparative Study of Epidural Steroid Injection Versus Mild® (Minimally Invasive Lumbar Decompression) Procedure in Patients Diagnosed With Symptomatic Moderate to Severe Lumbar Central Canal Stenosis
Brief Summary: This is a single-center, randomized, prospective, double-blind clinical study to assess the clinical application and outcomes with MILD® devices versus epidural steroid injection in patients with symptomatic moderate to severe central canal spinal stenosis.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Surgical decompression | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: Physical therapy | Intervention Type: PROCEDURE; Name: Surgical decompression; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Physical therapy; Assigned to Arm(s): 2
B: Arm Label: Vertos mild® Minimally-Invasive Lumbar Decompression; Type: ACTIVE_COMPARATOR; Interventions: Device: MILD® (Minimally Invasive Lumbar Decompression) | Arm Label: Epidural Steroid Injection; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epidural Steroid Injection | Intervention Type: DEVICE; Name: MILD® (Minimally Invasive Lumbar Decompression); Assigned to Arm(s): Vertos mild® Minimally-Invasive Lumbar Decompression | Intervention Type: DRUG; Name: Epidural Steroid Injection; Assigned to Arm(s): Epidural Steroid Injection
C: Arm Label: Surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Decompressive laminectomy, Other: Non-surgical treatments | Arm Label: Non-surgical treatments; Type: ACTIVE_COMPARATOR; Interventions: Other: Non-surgical treatments | Intervention Type: PROCEDURE; Name: Decompressive laminectomy; Assigned to Arm(s): Surgery | Intervention Type: OTHER; Name: Non-surgical treatments; Assigned to Arm(s): Non-surgical treatments, Surgery
D: Arm Label: Surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Decompressive laminectomy, Other: Non-surgical treatments, Procedure: Fusion--Instrumented, Procedure: Fusion-Non-instrumented | Arm Label: Non-surgical intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Non-surgical treatments | Intervention Type: PROCEDURE; Name: Decompressive laminectomy; Assigned to Arm(s): Surgery | Intervention Type: OTHER; Name: Non-surgical treatments; Assigned to Arm(s): Non-surgical intervention, Surgery | Intervention Type: PROCEDURE; Name: Fusion--Instrumented; Assigned to Arm(s): Surgery | Intervention Type: PROCEDURE; Name: Fusion-Non-instrumented; Assigned to Arm(s): Surgery

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Proof of Concept Study to Evaluate the Dose Response for the Systemic Benefit Risk Ratio of Inhaled Fluticasone Propionate in Chronic Obstructive Pulmonary Disease
Brief Summary: Chronic Obstructive Pulmonary Disease (COPD) is a major worldwide problem.Steroids inhalers are now an established treatment for COPD. Inhaled steroids can have a number of bad effects including suppression of the adrenal glands because of absorption. A previous study in patients with COPD.

C-reactive Protein (CRP) is a peptide produced in the liver in response to inflammation. Elevated circulating levels of CRP are associated with heart conditions. High levels of CRP have also been found in patients with COPD. In some studies, steroid inhalers have reduced CRP levels, and that of other inflammatory mediators, in patients with COPD. It is unknown whether this reflects a reduction in lung inflammation or an effect of systemically absorbed corticosteroid.

It is proposed to investigate the link between inhaled corticosteroid and serum CRP, lung inflammation (measured by exhaled nitric oxide) and systemic absorption of steroids.


Options:
A: Intervention Type: DRUG; Name: Salmeterol 50mcg/ Fluticasone Propionate 500mcg; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Advair; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Flovent; Assigned to Arm(s): N/A
C: Arm Label: MF/F MDI 400/10 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate/formoterol (MF/F) combination | Arm Label: MF/F MDI 200/10 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate/formoterol (MF/F) combination | Arm Label: MF MDI 400 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate MDI (MF MDI) | Arm Label: Formoterol MDI 10 mcg BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol MDI | Arm Label: Placebo MDI BID; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Mometasone furoate/formoterol (MF/F) combination; Assigned to Arm(s): MF/F MDI 400/10 mcg BID | Intervention Type: DRUG; Name: Mometasone furoate/formoterol (MF/F) combination; Assigned to Arm(s): MF/F MDI 200/10 mcg BID | Intervention Type: DRUG; Name: Mometasone furoate MDI (MF MDI); Assigned to Arm(s): MF MDI 400 mcg BID | Intervention Type: DRUG; Name: Formoterol MDI; Assigned to Arm(s): Formoterol MDI 10 mcg BID | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo MDI BID
D: Arm Label: Inhaled corticosteroid, Then placebo; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone propionate, Drug: Placebo | Arm Label: Placebo control, Then inhaled corticosteroid; Type: PLACEBO_COMPARATOR; Interventions: Drug: Fluticasone propionate, Drug: Placebo | Intervention Type: DRUG; Name: Fluticasone propionate; Assigned to Arm(s): Inhaled corticosteroid, Then placebo, Placebo control, Then inhaled corticosteroid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Inhaled corticosteroid, Then placebo, Placebo control, Then inhaled corticosteroid

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Proof of Concept Study to Evaluate the Dose Response for the Systemic Benefit Risk Ratio of Inhaled Fluticasone Propionate in Chronic Obstructive Pulmonary Disease
Brief Summary: Chronic Obstructive Pulmonary Disease (COPD) is a major worldwide problem.Steroids inhalers are now an established treatment for COPD. Inhaled steroids can have a number of bad effects including suppression of the adrenal glands because of absorption. A previous study in patients with COPD.

C-reactive Protein (CRP) is a peptide produced in the liver in response to inflammation. Elevated circulating levels of CRP are associated with heart conditions. High levels of CRP have also been found in patients with COPD. In some studies, steroid inhalers have reduced CRP levels, and that of other inflammatory mediators, in patients with COPD. It is unknown whether this reflects a reduction in lung inflammation or an effect of systemically absorbed corticosteroid.

It is proposed to investigate the link between inhaled corticosteroid and serum CRP, lung inflammation (measured by exhaled nitric oxide) and systemic absorption of steroids.


Options:
A: Intervention Type: DRUG; Name: Tiotropium bromide 18mcg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Fluticasone propionate/ salmeterol combination 50/500mcg; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: OTHER; Interventions: Drug: Fluticasone | Arm Label: 2; Type: OTHER; Interventions: Drug: Fluticasone, Drug: Comparator: Placebo | Intervention Type: DRUG; Name: Fluticasone; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Comparator: Placebo; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: Budesonide/formoterol pMDI; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Budesonide pMDI; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Formoterol Turbuhaler; Assigned to Arm(s): N/A
D: Arm Label: Inhaled corticosteroid, Then placebo; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone propionate, Drug: Placebo | Arm Label: Placebo control, Then inhaled corticosteroid; Type: PLACEBO_COMPARATOR; Interventions: Drug: Fluticasone propionate, Drug: Placebo | Intervention Type: DRUG; Name: Fluticasone propionate; Assigned to Arm(s): Inhaled corticosteroid, Then placebo, Placebo control, Then inhaled corticosteroid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Inhaled corticosteroid, Then placebo, Placebo control, Then inhaled corticosteroid

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 24 Week Multicenter, Randomized, Double-masked, Placebo Controlled Study to Assess the Difference in the Rate of Recurrent Exacerbations in Behçet¿s Patients With Posterior or Panuveitis Treated With AIN457 vs Placebo Adjunctive to Standard-of-care Immunosuppressive Therapy
Brief Summary: The purpose of this pivotal trial is to evaluate subcutaneous (SQ) AIN457 as an adjunctive therapy to reduce the rate of exacerbations of posterior uveitis or panuveitis secondary to Behçet's disease during the 24 weeks of study therapy as compared to standard of care alone.


Options:
A: Arm Label: AIN457 300mg s.c every 2 weeks; Type: EXPERIMENTAL; Interventions: Drug: AIN457 | Arm Label: AIN457 300mg s.c. every 4 weeks; Type: EXPERIMENTAL; Interventions: Drug: AIN457 | Arm Label: AIN457 150mg s.c every 4 weeks; Type: EXPERIMENTAL; Interventions: Drug: AIN457 | Arm Label: Placebo s.c every 2 weeks; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AIN457; Assigned to Arm(s): AIN457 300mg s.c every 2 weeks | Intervention Type: DRUG; Name: AIN457; Assigned to Arm(s): AIN457 150mg s.c every 4 weeks | Intervention Type: DRUG; Name: AIN457; Assigned to Arm(s): AIN457 300mg s.c. every 4 weeks | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo s.c every 2 weeks
B: Arm Label: AIN457C 300 mg every 2 week dosage regimen; Type: EXPERIMENTAL; Interventions: Drug: AIN457 | Arm Label: AIN457C 300 mg monthly dosage regimen; Type: EXPERIMENTAL; Interventions: Drug: AIN457 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AIN457; Assigned to Arm(s): AIN457C 300 mg every 2 week dosage regimen | Intervention Type: DRUG; Name: AIN457; Assigned to Arm(s): AIN457C 300 mg monthly dosage regimen | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: AIN457 300mg s.c weekly for 3 weeks; Type: EXPERIMENTAL; Interventions: Biological: AIN457 | Arm Label: AIN457 300mg s.c at baseline and Week 2; Type: EXPERIMENTAL; Interventions: Biological: AIN457 | Arm Label: AIN457 150mg s.c at baseline and Week 2; Type: EXPERIMENTAL; Interventions: Biological: AIN457 | Arm Label: Placebo s.c weekly for 3 weeks; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: AIN457; Assigned to Arm(s): AIN457 300mg s.c weekly for 3 weeks | Intervention Type: BIOLOGICAL; Name: AIN457; Assigned to Arm(s): AIN457 300mg s.c at baseline and Week 2 | Intervention Type: BIOLOGICAL; Name: AIN457; Assigned to Arm(s): AIN457 150mg s.c at baseline and Week 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo s.c weekly for 3 weeks
D: Arm Label: Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate | Arm Label: Mycophenolate mofetil; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mycophenolate mofetil | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Methotrexate | Intervention Type: DRUG; Name: Mycophenolate mofetil; Assigned to Arm(s): Mycophenolate mofetil

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vasopressin Receptor Agonists in Septic Shock: Effects on Microcirculation
Brief Summary: The present study was conducted as a prospective, randomized study to investigate the effects of vasopressin receptor agonists terlipressin and vasopressin on systemic hemodynamics and microcirculation in patients with catecholamine-dependent septic shock.


Options:
A: Arm Label: Angiotensin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Angiotensin II | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Angiotensin II | Intervention Type: DRUG; Name: Angiotensin II; Assigned to Arm(s): Angiotensin, Control
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Terlipressin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Vasopressin | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Norepinephrine | Intervention Type: DRUG; Name: Terlipressin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Vasopressin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Norepinephrine; Assigned to Arm(s): 3
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Early Goal Directed Therapy (EGDT) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: Protocolized Standard Care (PSC) | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Usual Care (UC) | Intervention Type: PROCEDURE; Name: Early Goal Directed Therapy (EGDT); Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Protocolized Standard Care (PSC); Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Usual Care (UC); Assigned to Arm(s): 3
D: Arm Label: continuous terlipressin; Type: EXPERIMENTAL; Interventions: Drug: continuous infusion of terlipressin | Arm Label: vasopressin; Type: EXPERIMENTAL; Interventions: Drug: Arginine vasopressin | Arm Label: terlipressin bolus dose; Type: EXPERIMENTAL; Interventions: Drug: terlipressin bolus administration | Intervention Type: DRUG; Name: continuous infusion of terlipressin; Assigned to Arm(s): continuous terlipressin | Intervention Type: DRUG; Name: Arginine vasopressin; Assigned to Arm(s): vasopressin | Intervention Type: DRUG; Name: terlipressin bolus administration; Assigned to Arm(s): terlipressin bolus dose

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Unilateral vs. Bilateral IBV Placement
Brief Summary: Patients with bilateral heterogeneous pulmonary emphysema benefit to differing degrees from unilateral ELVR with complete lobe closure in comparison with incomplete bilateral treatment.


Options:
A: Arm Label: PLVR; Type: EXPERIMENTAL; Interventions: Device: Polymeric Lung Volume Reduction System (PLVR) | Intervention Type: DEVICE; Name: Polymeric Lung Volume Reduction System (PLVR); Assigned to Arm(s): PLVR
B: Arm Label: bilateral; Type: ACTIVE_COMPARATOR; Interventions: Device: IBV Implantation | Arm Label: unilateral; Type: ACTIVE_COMPARATOR; Interventions: Device: IBV Implantation | Intervention Type: DEVICE; Name: IBV Implantation; Assigned to Arm(s): unilateral | Intervention Type: DEVICE; Name: IBV Implantation; Assigned to Arm(s): bilateral
C: Arm Label: Medical management; Type: NO_INTERVENTION; Interventions: Device: IBV Valve | Intervention Type: DEVICE; Name: IBV Valve; Assigned to Arm(s): Medical management
D: Arm Label: Chartis System-EBV Treatment; Type: OTHER; Interventions: Device: Chartis System, Device: Endobronchial Valve (EBV) Treatment | Intervention Type: DEVICE; Name: Chartis System; Assigned to Arm(s): Chartis System-EBV Treatment | Intervention Type: DEVICE; Name: Endobronchial Valve (EBV) Treatment; Assigned to Arm(s): Chartis System-EBV Treatment

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Brief Summary: This study is being conducted to determine if intravitreal injections of ranibizumab decrease the proportion of eyes in which vitrectomy is performed compared with saline injections in eyes presenting with vitreous hemorrhage from proliferative diabetic retinopathy.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Procedure: pars plana vitrectomy | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Procedure: pars plana vitrectomy | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: pars plana vitrectomy; Assigned to Arm(s): A, B
B: Arm Label: Avastin Injection Group (AIG); Type: EXPERIMENTAL; Interventions: Drug: Avastin (bevacizumab) | Arm Label: Sham Injection Group (SIG); Type: SHAM_COMPARATOR; Interventions: Other: Sham injection | Intervention Type: DRUG; Name: Avastin (bevacizumab); Assigned to Arm(s): Avastin Injection Group (AIG) | Intervention Type: OTHER; Name: Sham injection; Assigned to Arm(s): Sham Injection Group (SIG)
C: Arm Label: 7 days; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab | Arm Label: 20 days; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab | Arm Label: sham; Type: SHAM_COMPARATOR; Interventions: Other: sham | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): 20 days, 7 days | Intervention Type: OTHER; Name: sham; Assigned to Arm(s): sham
D: Arm Label: Saline Injection; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Arm Label: Ranibizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Ranibizumab | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Saline Injection

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Brief Summary: This study is being conducted to determine if intravitreal injections of ranibizumab decrease the proportion of eyes in which vitrectomy is performed compared with saline injections in eyes presenting with vitreous hemorrhage from proliferative diabetic retinopathy.


Options:
A: Arm Label: Panretinal photocoagulation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Panretinal photocoagulation | Arm Label: Bevacizumab + Panretinal Photocoagulation (PRP); Type: EXPERIMENTAL; Interventions: Procedure: Procedure: Panretinal Photocoagulation (PRP) Drug: Intravitreous injection of Bevacizumab | Intervention Type: PROCEDURE; Name: Panretinal photocoagulation; Assigned to Arm(s): Panretinal photocoagulation | Intervention Type: PROCEDURE; Name: Procedure: Panretinal Photocoagulation (PRP) Drug: Intravitreous injection of Bevacizumab; Assigned to Arm(s): Bevacizumab + Panretinal Photocoagulation (PRP)
B: Arm Label: SS-PRP arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravitreal Ranibizumabe, Drug: panfotocoagulation (PRP) single shoot (ETDRS) | Arm Label: MS-PRP arm; Type: EXPERIMENTAL; Interventions: Drug: Intravitreal Ranibizumabe, Drug: panfotocoagulation (PASCAL) | Arm Label: IVR arm; Type: OTHER; Interventions: Drug: Intravitreal Ranibizumabe | Intervention Type: DRUG; Name: Intravitreal Ranibizumabe; Assigned to Arm(s): IVR arm, MS-PRP arm, SS-PRP arm | Intervention Type: DRUG; Name: panfotocoagulation (PASCAL); Assigned to Arm(s): MS-PRP arm | Intervention Type: DRUG; Name: panfotocoagulation (PRP) single shoot (ETDRS); Assigned to Arm(s): SS-PRP arm
C: Arm Label: Placebo first (scheme 2); Type: OTHER; Interventions: Drug: potassium diclofenac | Arm Label: Diclofenac first (scheme 1); Type: OTHER; Interventions: Drug: potassium diclofenac | Intervention Type: DRUG; Name: potassium diclofenac; Assigned to Arm(s): Diclofenac first (scheme 1), Placebo first (scheme 2)
D: Arm Label: Saline Injection; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Arm Label: Ranibizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Ranibizumab | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Saline Injection

Answer: D